FINESSE BAKERY LIMITED
Company number 12514841 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
FINESSE BAKERY LIMITED - Analysis Report
Company Number: 12514841
Analysis Date: 2025-07-29 18:13 UTC
Financial Health Assessment for FINESSE BAKERY LIMITED (as of 31 March 2024)
1. Financial Health Score: D
Explanation:
The company shows signs of financial strain with a negative net asset position and high long-term liabilities relative to assets, indicating distress. Despite stable fixed assets and a slight increase in employees, the working capital situation is precarious. Improvements are needed to restore financial health and sustainability.
2. Key Vital Signs
| Metric | 2024 Value | Interpretation |
|---|---|---|
| Fixed Assets | £128,795 | Stable tangible asset base, likely property or equipment related to bakery operations, a positive sign of investment in production capacity. |
| Current Assets | £2,020 | Very low liquid assets (cash, stock, receivables), suggesting tight short-term liquidity. |
| Current Liabilities | £219,367 | Extremely high short-term debts due within a year, a significant red flag indicating liquidity risk. |
| Net Current Assets (Working Capital) | £279 | Barely positive but alarmingly low; indicates difficulty in covering immediate obligations. |
| Total Net Assets | -£90,293 | Negative net worth, meaning total liabilities exceed assets, reflecting financial distress. |
| Long-Term Liabilities | £219,367 | Large long-term debts relative to assets, raising solvency concerns. |
| Share Capital | £1.00 | Nominal share capital, typical for micro entities but offers minimal equity buffer. |
| Employee Count | 7 (2024) | Small workforce, consistent with micro company status, modest growth from 6 in previous year. |
3. Diagnosis
The financial "vital signs" of FINESSE BAKERY LIMITED reveal symptoms of serious financial distress:
Liquidity Strain: The company’s current assets have plummeted from £10,482 in 2023 to just £2,020 in 2024, while current liabilities remain extremely high at over £219,000. This is akin to a patient whose blood pressure (liquidity) has dangerously dropped, indicating the business may struggle to meet immediate financial obligations and pay creditors on time.
Negative Net Assets: The balance sheet shows net liabilities of £90,293, a critical symptom comparable to a failing organ. This means liabilities exceed the total of fixed and current assets, putting the company in a technically insolvent position on paper, which can undermine stakeholder confidence and limit access to finance.
High Debt Burden: The large amount classified as creditors falling due after more than one year (£219,367) indicates significant long-term debt. This long-term burden is a chronic condition that requires careful management and restructuring to prevent further deterioration.
Stable Fixed Assets: The fixed assets have remained constant, which is a good sign that the company has maintained its productive capacity and has not had to sell off assets to cover liabilities. However, this asset base is insufficient to offset the heavy liabilities.
Modest Workforce Growth: An increase in employee numbers from 6 to 7 suggests ongoing operations and potentially some growth or increased production capacity, despite financial challenges.
Overall, the company's financial health resembles a patient with chronic illness: it is surviving but weakened, with signs of stress that require immediate intervention to avoid collapse.
4. Recommendations
To restore financial wellness and improve the prognosis, the company should consider the following targeted actions:
Liquidity Management: Improve cash flow by tightening credit control, accelerating debtor collections, and controlling stock levels to avoid tying up cash unnecessarily. Explore short-term financing options to ease immediate pressures.
Debt Restructuring: Engage with creditors to negotiate more favorable payment terms or consider refinancing long-term liabilities to reduce short-term cash outflows and ease financial strain.
Cost Control: Review operating expenses to identify areas for cost reduction without impairing production quality, safeguarding margins and profitability.
Capital Injection: Seek additional equity investment or shareholder loans to improve the net asset position, providing a stronger financial buffer and enhancing creditor confidence.
Business Review & Strategy: Conduct a thorough strategic review to identify growth opportunities, optimize product mix, and enhance sales efforts. Exploring new markets or product innovation could improve revenue streams.
Professional Advice: Consider engaging financial advisors or turnaround specialists for expert guidance on restructuring and recovery plans.
Sign in to generate a free AI analysis of this company — no password needed, just an email link.